
Dr Saby George discusses the biological rationale for alternating pazopanib and bevacizumab in metastatic clear cell renal cell carcinoma.

Dr Saby George discusses the biological rationale for alternating pazopanib and bevacizumab in metastatic clear cell renal cell carcinoma.

Dr Jose Pablo Leone on where extrapolating female breast cancer data to men holds up and where it falls short, from endocrine therapy to PARP inhibitors.

Dr Wander discusses how SERENA-6 could reshape ctDNA testing and the timing of ESR1-directed treatment.

Matthew J. Frigault, MD, MS, discusses how the novel myeloma CAR T-cell therapy anitocabtagene autoleucel could reduce the need for extended surveillance for delayed toxicities.

Dr Jennifer Ligibel discusses BWEL quality-of-life results, why weight loss differed across groups, insurance barriers, and GLP-1 counseling.

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

New studies explore whether metformin, exercise, and GLP-1 drugs can blunt obesity-driven lung cancer risks, with trial results and new human research underway.

Disease progression rate and emerging ESR1 alterations help guide subsequent treatment decisions in HR+/HER2− breast cancer.

Ravi B. Parikh, MD, MPP, discusses how artificial intelligence could shape oncology practice, support personalized treatment decisions, and accelerate clinical research.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Bo Wang, MD, discusses the recent trial findings that he sees as having immediate relevance to oncologists treating lung cancers.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Karen E. Knudsen, PhD, discusses the greater significance of the INTerpath-001 results of intismeran autogene in resectable melanoma.

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

Kohei Shitara, MD, discusses safety and tolerability findings from G-HOPE-001 evaluating arcotatug tavatecan in previously treated, CLDN18.2-positive advanced gastric cancer.

Benjamin Garmezy, MD, discusses how JNJ-6143 uses a novel RIPTAC mechanism to target AR and BRD4, potentially addressing resistance-associated genomic alterations in advanced prostate cancer.

Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The oncologist discusses resistance mechanisms and the need to evaluate whether investigational JNJ-6143 can provide durable responses in earlier prostate cancer treatment settings.

Two researchers explain why Asian American and Hispanic patients with breast cancer are hard to see in the data, and what better data could change.

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.

Bo Wang, MD, discusses the positive outcomes for divarasib vs other KRAS G12C inhibitors in non–small cell lung cancer.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.